ELISpot and FluoroSpot Assay Market by Product (Assay kit (Technique, Utility, Analyte (T Cell and B Cell assay)), Analyzer), Application (Transplants, Infectious Diseases, Vaccine Development, Cancer Research), End User - Global Forecast to 2028
The global ELISpot and FluoroSpot Assays Market is expected to reach USD 421 million by 2028 from USD 292 million in 2023, at a CAGR of 7.6% during the forecast period. Market is driven by factors such as Increasing use of ELISpot and FluoroSpot assays in oncology, growth in biotechnology and biopharmaceutical industries. On the other hand, availability of alternative detection technologies is expected to limit market growth to a certain extent in the coming years.
“The Assay kits accounted for the largest market share in the ELISpot and FluoroSpot Assays product’ smarket, during the forecast period”
The ELISpot and FluoroSpot Assay Products market is segmented into Assay kits, Analyzers, and Ancillary Products. In 2022, kits accounted for a sizable market share because they offer advantages in terms of high specificity and sensitivity and better detection limits as compared to other assays such as ELISA as well as their wide applications in the field of research and diagnostics.
“Diagnostic application segment accounted for the largest market share”
Based on type of application, the ELISpot and FluoroSpot Assays market is segmented into Diagnostic and Research Application. The Diagnostic application segment accounted for the largest market share in 2022., while research application is expected to grow at the fastest rate in the years ahead, from 2023 to 2028 considering their practice in several research applications, such as vaccine development, clinical trials, and cancer research.
“APAC region accounted for the highest CAGR”
The global ELISpot and FluoroSpot Assays market is divided into four regions: North America, Asia-Pacific, Europe, and Rest of the World. According to the regional analysis, the Asia-Pacific region is likely to retain a significant market share in 2022 and the future. The Asia-Pacific market is being propelled by an increase in non-communicable (NCD), research funding on vaccines and changing disease profiles. North America, on the other hand, will experience significant growth in the coming years due to the presence of key players, the availability of technologically advanced ELISpot and FluoroSpot assay kits and analyzers.
“Europe is estimated to register the third highest CAGR during the forecast period.”
In this report, the ELISpot and FluoroSpot Assays market is segmented into four major regional segments: North America, Europe, Asia Pacific, Rest of the world. The market in Europe is projected to register the third highest growth rate during the forecast period. The growth in this market is due to Europe has a strong tradition of research and academic excellence, the rising incidence of chronic diseases, including autoimmune disorders and infectious diseases, government funding for research and healthcare in many European countries supports the development and adoption of advanced diagnostic technologies.
The primary interviews conducted for this report can be categorized as follows:
This report studies the ELISpot and FluoroSpot Assays market based on product, applications, End user, and region. The report also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total ELISpot and FluoroSpot Assays market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
Market Drivers: Comprehensive information about driving factors of the markets. The report analyses the markets drivers across key geographic regions.
Market Penetration: Comprehensive information on ELISpot and FluoroSpot assay products offered by the top 25 players in the market. The report analyses the ELISpot and FluoroSpot Assays market by product, application, end user and region.
Market Development: Comprehensive information about lucrative emerging markets. The report analyses the markets for various securement devices across key geographic regions.
Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the ELISpot and FluoroSpot Assays market
Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the ELISpot and FluoroSpot Assays market
Market Position: It will upkeep stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.
“The Assay kits accounted for the largest market share in the ELISpot and FluoroSpot Assays product’ smarket, during the forecast period”
The ELISpot and FluoroSpot Assay Products market is segmented into Assay kits, Analyzers, and Ancillary Products. In 2022, kits accounted for a sizable market share because they offer advantages in terms of high specificity and sensitivity and better detection limits as compared to other assays such as ELISA as well as their wide applications in the field of research and diagnostics.
“Diagnostic application segment accounted for the largest market share”
Based on type of application, the ELISpot and FluoroSpot Assays market is segmented into Diagnostic and Research Application. The Diagnostic application segment accounted for the largest market share in 2022., while research application is expected to grow at the fastest rate in the years ahead, from 2023 to 2028 considering their practice in several research applications, such as vaccine development, clinical trials, and cancer research.
“APAC region accounted for the highest CAGR”
The global ELISpot and FluoroSpot Assays market is divided into four regions: North America, Asia-Pacific, Europe, and Rest of the World. According to the regional analysis, the Asia-Pacific region is likely to retain a significant market share in 2022 and the future. The Asia-Pacific market is being propelled by an increase in non-communicable (NCD), research funding on vaccines and changing disease profiles. North America, on the other hand, will experience significant growth in the coming years due to the presence of key players, the availability of technologically advanced ELISpot and FluoroSpot assay kits and analyzers.
“Europe is estimated to register the third highest CAGR during the forecast period.”
In this report, the ELISpot and FluoroSpot Assays market is segmented into four major regional segments: North America, Europe, Asia Pacific, Rest of the world. The market in Europe is projected to register the third highest growth rate during the forecast period. The growth in this market is due to Europe has a strong tradition of research and academic excellence, the rising incidence of chronic diseases, including autoimmune disorders and infectious diseases, government funding for research and healthcare in many European countries supports the development and adoption of advanced diagnostic technologies.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
- By Designation: C-level - 30%, D-level - 34%, and Others - 36%
- By Region: North America - 40%, Europe - 28%, Asia Pacific - 20%, and the Rest of the World – 12%
- Oxford Immunotec USA, Inc. (Subsidiary of Revvity Inc.) (UK)
- Becton, Dickinson and Company (BD) (US)
- Cellular Technology Limited (CTL) (US)
- Mabtech (Sweden)
- Abcam plc. (UK)
- Bio-Techne (US)
- Merck KGaA (Germany)
- Autoimmun Diagnostika GmbH (Germany)
- U-CyTech (Netherland)
- Mikrogen Diagnostik (Germany)
- Medix Biochemica (Finland)
- Abnova Corporation (Taiwan)
- Anogen-Yes Biotech Laboratories Ltd. (Canada)
- Biorbyt Ltd (UK)
- BIOSYS Scientific Devices GmbH (Germany)
- Jackson ImmunoResearch Inc. (US)
- iST Scientific (UK)
- SERVA Electrophoresis GmbH (Germany)
- ACROBiosystems (US)
- NATIONAL ANALYTICAL CORPORATION (India)
- STEMCELL Technologies. (Canada)
- ZenBio, Inc (US)
- BOC Sciences (US)
- Tokyo Chemical Industry Co., Ltd. (TCI) (Japan)
- MP Biomedicals (California)
This report studies the ELISpot and FluoroSpot Assays market based on product, applications, End user, and region. The report also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total ELISpot and FluoroSpot Assays market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
Market Drivers: Comprehensive information about driving factors of the markets. The report analyses the markets drivers across key geographic regions.
Market Penetration: Comprehensive information on ELISpot and FluoroSpot assay products offered by the top 25 players in the market. The report analyses the ELISpot and FluoroSpot Assays market by product, application, end user and region.
Market Development: Comprehensive information about lucrative emerging markets. The report analyses the markets for various securement devices across key geographic regions.
Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the ELISpot and FluoroSpot Assays market
Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the ELISpot and FluoroSpot Assays market
Market Position: It will upkeep stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONAL SEGMENTATION
1.3.3 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.8 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: OXFORD IMMUNOTEC USA, INC. (SUBSIDIARY OF REVVITY, INC.) (UK)
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.1 GROWTH FORECAST
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 8 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT
2.7 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 10 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 11 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 12 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 13 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 ELISPOT AND FLUOROSPOT ASSAYS MARKET OVERVIEW
FIGURE 14 RISING INCIDENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET
4.2 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY TECHNIQUE, 2023–2028
FIGURE 15 ELISPOT ASSAY KITS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
4.3 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT AND COUNTRY (2022)
FIGURE 16 ASSAY KITS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN ELISPOT AND FLUOROSPOT ASSAYS MARKET IN 2022
4.4 ELISPOT AND FLUOROSPOT ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 ELISPOT AND FLUOROSPOT ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
FIGURE 19 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
5.2.1.2 Increasing vaccine development to address challenges of antimicrobial resistance
5.2.1.3 Increasing use of ELISpot and FluoroSpot assays in oncology
TABLE 3 INCIDENCE OF CANCER IN MEN, 2020
TABLE 4 INCIDENCE OF CANCER IN WOMEN, 2020
5.2.1.4 ELISpot assays as diagnostic tool in drug hypersensitivity reaction
TABLE 5 EXAMPLES OF ELISPOT ASSAYS IN DRUG HYPERSENSITIVITY REACTIONS
5.2.1.5 Growth in biotechnology and biopharmaceutical industries
5.2.2 RESTRAINTS
5.2.2.1 Stringent requirements for approval of ELISpot and FluoroSpot assay instruments and consumables
5.2.2.2 High cost of assay kits and analyzers
5.2.3 OPPORTUNITIES
5.2.3.1 Use of FluoroSpot assays for multiple-analyte detection in single well
5.2.3.2 Emerging economies
FIGURE 20 HEALTHCARE EXPENDITURE PER CAPITA IN BRIC COUNTRIES, 2012–2020
5.2.4 CHALLENGES
5.2.4.1 Availability of alternative detection technologies
5.2.4.2 Dearth of skilled professionals
5.3 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 22 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.5 TECHNOLOGY ANALYSIS
5.6 PORTER’S FIVE FORCES ANALYSIS
5.6.1 THREAT OF NEW ENTRANTS
5.6.2 INTENSITY OF COMPETITIVE RIVALRY
5.6.3 BARGAINING POWER OF BUYERS
5.6.4 BARGAINING POWER OF SUPPLIERS
5.6.5 THREAT OF SUBSTITUTES
5.7 KEY STAKEHOLDERS AND BUYING CRITERIA
5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
TABLE 6 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%)
5.7.2 BUYING CRITERIA
FIGURE 24 KEY BUYING CRITERIA FOR END USERS
TABLE 7 KEY BUYING CRITERIA FOR END USERS
5.8 REGULATORY LANDSCAPE
TABLE 8 REGULATORY AUTHORITIES GOVERNING ELISPOT AND FLUOROSPOT ASSAYS MARKET
5.8.1 US
TABLE 9 US: CLASSIFICATION OF ELISPOT AND FLUOROSPOT ASSAY PRODUCTS
FIGURE 25 US: REGULATORY PROCESS FOR IVD DEVICES
5.8.2 CANADA
FIGURE 26 CANADA: REGULATORY PROCESS FOR IVD DEVICES
5.8.3 EUROPE
TABLE 10 EUROPE: CLASSIFICATION OF IVD DEVICES
5.8.4 JAPAN
FIGURE 27 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
TABLE 11 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.8.5 CHINA
TABLE 12 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.8.6 INDIA
FIGURE 28 INDIA: REGULATORY PROCESS FOR IVD DEVICES
5.8.7 RUSSIA
TABLE 13 RUSSIA: CLASSIFICATION OF IVD DEVICES
5.8.8 SAUDI ARABIA
TABLE 14 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.8.9 MEXICO
FIGURE 29 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
TABLE 15 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.8.10 BRAZIL
FIGURE 30 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
5.8.11 SOUTH KOREA
TABLE 16 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.8.12 MIDDLE EAST
5.8.13 AFRICA
5.9 KEY CONFERENCES AND EVENTS
TABLE 17 LIST OF CONFERENCES AND EVENTS, 2023–2025
5.10 PATENT ANALYSIS
FIGURE 31 PATENT ANALYSIS FOR ELISPOT AND FLUOROSPOT ASSAYS
5.11 PRICING ANALYSIS
TABLE 18 ELISPOT AND FLUOROSPOT ASSAYS MARKET: PRICE RANGE FOR ELISPOT AND FLUOROSPOT ASSAY PRODUCTS
TABLE 19 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (2022)
5.12 TRADE ANALYSIS
5.12.1 TRADE ANALYSIS FOR ELISPOT AND FLUOROSPOT ASSAYS
TABLE 20 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2017–2022 (USD MILLION)
TABLE 21 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2017–2022 (USD MILLION)
5.13 ECOSYSTEM ANALYSIS
5.13.1 ROLE IN ECOSYSTEM
FIGURE 32 KEY PLAYERS OPERATING IN ELISPOT AND FLUOROSPOT ASSAYS MARKET
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
6 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 22 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
6.2 ASSAY KITS
TABLE 23 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 24 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 25 EUROPE: ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 26 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.2.1 ASSAY KITS MARKET, BY TECHNIQUE
TABLE 27 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION)
6.2.1.1 ELISpot assay kits
6.2.1.1.1 Need for highly sensitive immune monitoring requirements in clinical trials to drive market
TABLE 28 ELISPOT ASSAY KITS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 29 NORTH AMERICA: ELISPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 30 EUROPE: ELISPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 31 ASIA PACIFIC: ELISPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.2.1.2 FluoroSpot assay kits
6.2.1.2.1 Increasing demand for multiple analyte detection and technological advancements to support market growth
TABLE 32 FLUOROSPOT ASSAY KITS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 33 NORTH AMERICA: FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 34 EUROPE: FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 35 ASIA PACIFIC: FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.2.2 ASSAY KITS MARKET, BY UTILITY
TABLE 36 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY UTILITY, 2020–2028 (USD MILLION)
6.2.2.1 Diagnostic kits
6.2.2.1.1 Need for early diagnosis of infections to drive market
TABLE 37 CANCER CASES, BY TYPE, 2020
TABLE 38 DIAGNOSTIC KITS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 39 NORTH AMERICA: DIAGNOSTIC KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 40 EUROPE: DIAGNOSTIC KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 41 ASIA PACIFIC: DIAGNOSTIC KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.2.2.2 Research kits
6.2.2.2.1 Increasing investments in vaccine research, clinical trials, and cancer research to drive market
TABLE 42 RESEARCH KITS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 43 NORTH AMERICA: RESEARCH KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 44 EUROPE: RESEARCH KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 45 ASIA PACIFIC: RESEARCH KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.2.3 ASSAY KITS MARKET, BY ANALYTE
TABLE 46 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY ANALYTE, 2020–2028 (USD MILLION)
6.2.3.1 T-cell-based kits
6.2.3.1.1 Low concentrations of infection-released analytes necessitate use of T-cell-based kits
TABLE 47 T-CELL-BASED KITS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 48 NORTH AMERICA: T-CELL-BASED KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 49 EUROPE: T-CELL-BASED KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 50 ASIA PACIFIC: T-CELL-BASED KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.2.3.2 B-cell-based kits
6.2.3.2.1 Detection of B-cell-based antibodies useful to study cell response post-infection/vaccination
TABLE 51 B-CELL-BASED KITS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 52 NORTH AMERICA: B-CELL-BASED KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 53 EUROPE: B-CELL-BASED KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 54 ASIA PACIFIC: B-CELL-BASED KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.2.3.3 Other analyte kits
TABLE 55 OTHER ANALYTE KITS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 56 NORTH AMERICA: OTHER ANALYTE KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 57 EUROPE: OTHER ANALYTE KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 58 ASIA PACIFIC: OTHER ANALYTE KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.3 ANALYZERS
6.3.1 ADOPTION OF ASSAY KITS TO DRIVE USE OF ANALYZERS
TABLE 59 ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 60 NORTH AMERICA: ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 61 EUROPE: ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 62 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.4 ANCILLARY PRODUCTS
6.4.1 REPEATED USAGE OF ANCILLARY PRODUCTS INTEGRAL TO RELIABILITY AND SUCCESS OF ELISPOT AND FLUOROSPOT ASSAYS
TABLE 63 ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 64 NORTH AMERICA: ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 65 EUROPE: ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 66 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
7 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION
7.1 INTRODUCTION
TABLE 67 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
7.2 DIAGNOSTIC APPLICATIONS
TABLE 68 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2028 (USD MILLION)
TABLE 69 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2028 (USD MILLION)
TABLE 70 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 71 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 72 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2028 (USD MILLION)
7.2.1 INFECTIOUS DISEASES
7.2.1.1 Rising prevalence of infectious diseases to drive market
TABLE 73 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2028 (USD MILLION)
TABLE 74 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 75 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 76 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2028 (USD MILLION)
7.2.2 TRANSPLANTS
7.2.2.1 Growing incidence of infections caused during transplant procedures to drive demand
FIGURE 33 PATIENTS ON WAITING LIST FOR ORGAN TRANSPLANTS, 2023
FIGURE 34 NUMBER OF TRANSPLANTS PERFORMED IN 2023
TABLE 77 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY REGION, 2020–2028 (USD MILLION)
TABLE 78 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 79 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 80 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY COUNTRY, 2020–2028 (USD MILLION)
7.3 RESEARCH APPLICATIONS
TABLE 81 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2028 (USD MILLION)
TABLE 82 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2028 (USD MILLION)
TABLE 83 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 84 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 85 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2028 (USD MILLION)
7.3.1 VACCINE DEVELOPMENT
7.3.1.1 Largest and fastest-growing segment of market
TABLE 86 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY REGION, 2020–2028 (USD MILLION)
TABLE 87 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 88 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 89 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2020–2028 (USD MILLION)
7.3.2 CLINICAL TRIALS
7.3.2.1 Growing number of clinical trials to drive demand
FIGURE 35 NUMBER OF CLINICAL TRIALS, BY REGION, 2010–2021
FIGURE 36 NUMBER OF REGISTERED CLINICAL STUDIES, 2023
TABLE 90 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY REGION, 2020–2028 (USD MILLION)
TABLE 91 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 92 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 93 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2020–2028 (USD MILLION)
7.3.3 CANCER RESEARCH
7.3.3.1 Rising prevalence of cancer to support market growth
TABLE 94 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY REGION, 2020–2028 (USD MILLION)
TABLE 95 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 96 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 97 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY COUNTRY, 2020–2028 (USD MILLION)
8 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER
8.1 INTRODUCTION
TABLE 98 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
8.2 HOSPITAL AND CLINICAL LABORATORIES
8.2.1 IMPROVING HEALTHCARE INFRASTRUCTURE IN DEVELOPING COUNTRIES TO DRIVE MARKET
TABLE 99 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY REGION, 2020–2028 (USD MILLION)
TABLE 100 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 101 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 102 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY COUNTRY, 2020–2028 (USD MILLION)
8.3 RESEARCH INSTITUTES
8.3.1 FASTEST-GROWING END USER OF ELISPOT AND FLUOROSPOT ASSAYS
TABLE 103 GRANTS, BY CANCER TYPE, 2023
TABLE 104 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2020–2028 (USD MILLION)
TABLE 105 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 106 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 107 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020–2028 (USD MILLION)
8.4 BIOPHARMACEUTICAL COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS
8.4.1 GROWTH IN BIOTECHNOLOGY INDUSTRY TO PROPEL GROWTH
TABLE 108 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY REGION, 2020–2028 (USD MILLION)
TABLE 109 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 110 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 111 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2020–2028 (USD MILLION)
9 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION
9.1 INTRODUCTION
TABLE 112 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION, 2020–2028 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 37 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET SNAPSHOT
TABLE 113 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 114 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 115 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 116 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.2.1 NORTH AMERICA: RECESSION IMPACT
9.2.2 US
9.2.2.1 Rising prevalence of chronic diseases to drive market
TABLE 117 US: KEY MACROINDICATORS
TABLE 118 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 119 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 120 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.2.3 CANADA
9.2.3.1 Rising healthcare expenditure to drive adoption of ELISpot and FluoroSpot assays
TABLE 121 CANADA: KEY MACROINDICATORS
TABLE 122 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 123 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 124 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.3 EUROPE
TABLE 125 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY
9.3.1 EUROPE: RECESSION IMPACT
TABLE 126 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 127 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 128 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 129 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.3.2 GERMANY
9.3.2.1 Fastest-growing country in European ELISpot and FluoroSpot assays market
TABLE 130 GERMANY: KEY MACROINDICATORS
TABLE 131 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 132 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 133 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.3.3 UK
9.3.3.1 Rising prevalence of NCDs to drive market
TABLE 134 UK: KEY MACROINDICATORS
TABLE 135 UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 136 UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 137 UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.3.4 FRANCE
9.3.4.1 Need for early disease diagnosis to support market growth
TABLE 138 FRANCE: KEY MACROINDICATORS
TABLE 139 FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 140 FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 141 FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.3.5 ITALY
9.3.5.1 Increasing incidence of cancer to propel market
TABLE 142 ITALY: KEY MACROINDICATORS
TABLE 143 ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 144 ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 145 ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.3.6 SPAIN
9.3.6.1 High incidence of chronic diseases to drive market
TABLE 146 SPAIN: KEY MACROINDICATORS
TABLE 147 SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 148 SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 149 SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.3.7 REST OF EUROPE
TABLE 150 REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 151 REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 152 REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 38 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET SNAPSHOT
TABLE 153 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 154 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 155 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 156 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.4.2 CHINA
9.4.2.1 Rising focus on vaccine development and cancer research to drive market
TABLE 157 CHINA: KEY MACROINDICATORS
TABLE 158 CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 159 CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 160 CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.4.3 JAPAN
9.4.3.1 Increased focus on vaccine research to support market growth
TABLE 161 JAPAN: KEY MACROINDICATORS
TABLE 162 JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 163 JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 164 JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.4.4 INDIA
9.4.4.1 Increasing focus on cancer research and therapy to drive market
TABLE 165 INDIA: KEY MACROINDICATORS
TABLE 166 INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 167 INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 168 INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.4.5 REST OF ASIA PACIFIC
TABLE 169 REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 170 REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 171 REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.5 REST OF THE WORLD
TABLE 172 REST OF THE WORLD: POPULATION AGED 65 AND ABOVE, 2022
9.5.1 REST OF THE WORLD: RECESSION IMPACT
TABLE 173 REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 174 REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 175 REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 STRATEGIES ADOPTED BY KEY PLAYERS
TABLE 176 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ELISPOT AND FLUOROSPOT ASSAYS MARKET
10.3 MARKET SHARE ANALYSIS
TABLE 177 ELISPOT AND FLUOROSPOT ASSAYS MARKET: DEGREE OF COMPETITION
10.4 REVENUE SHARE ANALYSIS
FIGURE 39 REVENUE ANALYSIS OF KEY PUBLIC PLAYERS IN ELISPOT AND FLUOROSPOT ASSAYS MARKET
FIGURE 40 ELISPOT AND FLUOROSPOT ASSAYS: MARKET RANKING ANALYSIS, 2022
10.5 COMPANY EVALUATION MATRIX
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
FIGURE 41 ELISPOT AND FLUOROSPOT ASSAYS MARKET: COMPANY EVALUATION MATRIX, 2022
10.6 SME/STARTUP EVALUATION MATRIX
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
FIGURE 42 ELISPOT AND FLUOROSPOT ASSAYS MARKET: SME/STARTUP EVALUATION MATRIX, 2022
10.7 COMPETITIVE BENCHMARKING
TABLE 178 ELISPOT AND FLUOROSPOT ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
10.8 COMPANY FOOTPRINT
TABLE 179 COMPANY FOOTPRINT
TABLE 180 PRODUCT FOOTPRINT
TABLE 181 REGIONAL FOOTPRINT
10.9 COMPETITIVE SCENARIO
10.9.1 PRODUCT LAUNCHES
TABLE 182 KEY PRODUCT LAUNCHES, JANUARY 2020–OCTOBER 2023
10.9.2 DEALS
TABLE 183 KEY DEALS, JANUARY 2020–OCTOBER 2023
10.9.3 OTHER DEVELOPMENTS
TABLE 184 OTHER KEY DEVELOPMENTS, JANUARY 2020–OCTOBER 2023
11 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
11.1 KEY PLAYERS
11.1.1 OXFORD IMMUNOTEC USA, INC. (SUBSIDIARY OF REVVITY, INC.)
TABLE 185 OXFORD IMMUNOTEC USA, INC. (SUBSIDIARY OF REVVITY, INC.): BUSINESS OVERVIEW
FIGURE 43 REVVITY, INC.: COMPANY SNAPSHOT (2023)
11.1.2 BECTON, DICKINSON AND COMPANY
TABLE 186 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 44 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
11.1.3 BIO-TECHNE
TABLE 187 BIO-TECHNE: BUSINESS OVERVIEW
FIGURE 45 BIO-TECHNE: COMPANY SNAPSHOT (2023)
11.1.4 CELLULAR TECHNOLOGY LIMITED
TABLE 188 CELLULAR TECHNOLOGY LIMITED: BUSINESS OVERVIEW
11.1.5 MABTECH
TABLE 189 MABTECH: BUSINESS OVERVIEW
11.1.6 ABCAM PLC
TABLE 190 ABCAM PLC: BUSINESS OVERVIEW
FIGURE 46 ABCAM PLC: COMPANY SNAPSHOT (2022)
11.1.7 MERCK KGAA
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 47 MERCK KGAA: COMPANY SNAPSHOT (2022)
11.1.8 AUTOIMMUN DIAGNOSTIKA GMBH
TABLE 192 AUTOIMMUN DIAGNOSTIKA GMBH: BUSINESS OVERVIEW
11.1.9 U-CYTECH
TABLE 193 U-CYTECH: BUSINESS OVERVIEW
11.1.10 MIKROGEN DIAGNOSTIK
TABLE 194 MIKROGEN DIAGNOSTIK: BUSINESS OVERVIEW
11.1.11 MEDIX BIOCHEMICA
TABLE 195 MEDIX BIOCHEMICA: BUSINESS OVERVIEW
11.1.12 ABNOVA CORPORATION
TABLE 196 ABNOVA CORPORATION: BUSINESS OVERVIEW
11.1.13 ANOGEN-YES BIOTECH LABORATORIES LTD.
TABLE 197 ANOGEN-YES BIOTECH LABORATORIES LTD.: BUSINESS OVERVIEW
11.1.14 BIORBYT LTD.
TABLE 198 BIORBYT LTD.: BUSINESS OVERVIEW
11.1.15 BIOSYS SCIENTIFIC DEVICES GMBH
TABLE 199 BIOSYS SCIENTIFIC DEVICES GMBH: BUSINESS OVERVIEW
11.2 OTHER PLAYERS
11.2.1 JACKSON IMMUNORESEARCH INC.
TABLE 200 JACKSON IMMUNORESEARCH INC.: BUSINESS OVERVIEW
11.2.2 IST SCIENTIFIC
TABLE 201 IST SCIENTIFIC: BUSINESS OVERVIEW
11.2.3 SERVA ELECTROPHORESIS GMBH
TABLE 202 SERVA ELECTROPHORESIS GMBH: BUSINESS OVERVIEW
11.2.4 ACROBIOSYSTEMS
TABLE 203 ACROBIOSYSTEMS: BUSINESS OVERVIEW
11.2.5 NATIONAL ANALYTICAL CORPORATION
TABLE 204 NATIONAL ANALYTICAL CORPORATION: BUSINESS OVERVIEW
11.2.6 STEMCELL TECHNOLOGIES
TABLE 205 STEMCELL TECHNOLOGIES: BUSINESS OVERVIEW
11.2.7 ZENBIO, INC.
TABLE 206 ZENBIO, INC.: BUSINESS OVERVIEW
11.2.8 BOC SCIENCES
TABLE 207 BOC SCIENCES: BUSINESS OVERVIEW
11.2.9 TOKYO CHEMICAL INDUSTRY CO., LTD.
TABLE 208 TOKYO CHEMICAL INDUSTRY CO., LTD.: BUSINESS OVERVIEW
11.2.10 MP BIOMEDICALS
TABLE 209 MP BIOMEDICALS: BUSINESS OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
12 APPENDIX
12.1 INSIGHTS FROM INDUSTRY EXPERTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 CUSTOMIZATION OPTIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONAL SEGMENTATION
1.3.3 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.8 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: OXFORD IMMUNOTEC USA, INC. (SUBSIDIARY OF REVVITY, INC.) (UK)
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.1 GROWTH FORECAST
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 8 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT
2.7 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 10 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 11 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 12 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 13 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
4 PREMIUM INSIGHTS
4.1 ELISPOT AND FLUOROSPOT ASSAYS MARKET OVERVIEW
FIGURE 14 RISING INCIDENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET
4.2 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY TECHNIQUE, 2023–2028
FIGURE 15 ELISPOT ASSAY KITS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
4.3 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT AND COUNTRY (2022)
FIGURE 16 ASSAY KITS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN ELISPOT AND FLUOROSPOT ASSAYS MARKET IN 2022
4.4 ELISPOT AND FLUOROSPOT ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 ELISPOT AND FLUOROSPOT ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis
FIGURE 19 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
TABLE 2 GLOBAL INCIDENCE OF INFECTIOUS DISEASES
5.2.1.2 Increasing vaccine development to address challenges of antimicrobial resistance
5.2.1.3 Increasing use of ELISpot and FluoroSpot assays in oncology
TABLE 3 INCIDENCE OF CANCER IN MEN, 2020
TABLE 4 INCIDENCE OF CANCER IN WOMEN, 2020
5.2.1.4 ELISpot assays as diagnostic tool in drug hypersensitivity reaction
TABLE 5 EXAMPLES OF ELISPOT ASSAYS IN DRUG HYPERSENSITIVITY REACTIONS
5.2.1.5 Growth in biotechnology and biopharmaceutical industries
5.2.2 RESTRAINTS
5.2.2.1 Stringent requirements for approval of ELISpot and FluoroSpot assay instruments and consumables
5.2.2.2 High cost of assay kits and analyzers
5.2.3 OPPORTUNITIES
5.2.3.1 Use of FluoroSpot assays for multiple-analyte detection in single well
5.2.3.2 Emerging economies
FIGURE 20 HEALTHCARE EXPENDITURE PER CAPITA IN BRIC COUNTRIES, 2012–2020
5.2.4 CHALLENGES
5.2.4.1 Availability of alternative detection technologies
5.2.4.2 Dearth of skilled professionals
5.3 VALUE CHAIN ANALYSIS
FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 22 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.5 TECHNOLOGY ANALYSIS
5.6 PORTER’S FIVE FORCES ANALYSIS
5.6.1 THREAT OF NEW ENTRANTS
5.6.2 INTENSITY OF COMPETITIVE RIVALRY
5.6.3 BARGAINING POWER OF BUYERS
5.6.4 BARGAINING POWER OF SUPPLIERS
5.6.5 THREAT OF SUBSTITUTES
5.7 KEY STAKEHOLDERS AND BUYING CRITERIA
5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
TABLE 6 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%)
5.7.2 BUYING CRITERIA
FIGURE 24 KEY BUYING CRITERIA FOR END USERS
TABLE 7 KEY BUYING CRITERIA FOR END USERS
5.8 REGULATORY LANDSCAPE
TABLE 8 REGULATORY AUTHORITIES GOVERNING ELISPOT AND FLUOROSPOT ASSAYS MARKET
5.8.1 US
TABLE 9 US: CLASSIFICATION OF ELISPOT AND FLUOROSPOT ASSAY PRODUCTS
FIGURE 25 US: REGULATORY PROCESS FOR IVD DEVICES
5.8.2 CANADA
FIGURE 26 CANADA: REGULATORY PROCESS FOR IVD DEVICES
5.8.3 EUROPE
TABLE 10 EUROPE: CLASSIFICATION OF IVD DEVICES
5.8.4 JAPAN
FIGURE 27 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
TABLE 11 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.8.5 CHINA
TABLE 12 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.8.6 INDIA
FIGURE 28 INDIA: REGULATORY PROCESS FOR IVD DEVICES
5.8.7 RUSSIA
TABLE 13 RUSSIA: CLASSIFICATION OF IVD DEVICES
5.8.8 SAUDI ARABIA
TABLE 14 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.8.9 MEXICO
FIGURE 29 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
TABLE 15 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.8.10 BRAZIL
FIGURE 30 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
5.8.11 SOUTH KOREA
TABLE 16 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.8.12 MIDDLE EAST
5.8.13 AFRICA
5.9 KEY CONFERENCES AND EVENTS
TABLE 17 LIST OF CONFERENCES AND EVENTS, 2023–2025
5.10 PATENT ANALYSIS
FIGURE 31 PATENT ANALYSIS FOR ELISPOT AND FLUOROSPOT ASSAYS
5.11 PRICING ANALYSIS
TABLE 18 ELISPOT AND FLUOROSPOT ASSAYS MARKET: PRICE RANGE FOR ELISPOT AND FLUOROSPOT ASSAY PRODUCTS
TABLE 19 AVERAGE SELLING PRICE OF PRODUCTS OFFERED BY KEY PLAYERS (2022)
5.12 TRADE ANALYSIS
5.12.1 TRADE ANALYSIS FOR ELISPOT AND FLUOROSPOT ASSAYS
TABLE 20 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2017–2022 (USD MILLION)
TABLE 21 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2017–2022 (USD MILLION)
5.13 ECOSYSTEM ANALYSIS
5.13.1 ROLE IN ECOSYSTEM
FIGURE 32 KEY PLAYERS OPERATING IN ELISPOT AND FLUOROSPOT ASSAYS MARKET
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
6 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 22 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
6.2 ASSAY KITS
TABLE 23 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 24 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 25 EUROPE: ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 26 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.2.1 ASSAY KITS MARKET, BY TECHNIQUE
TABLE 27 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY TECHNIQUE, 2020–2028 (USD MILLION)
6.2.1.1 ELISpot assay kits
6.2.1.1.1 Need for highly sensitive immune monitoring requirements in clinical trials to drive market
TABLE 28 ELISPOT ASSAY KITS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 29 NORTH AMERICA: ELISPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 30 EUROPE: ELISPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 31 ASIA PACIFIC: ELISPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.2.1.2 FluoroSpot assay kits
6.2.1.2.1 Increasing demand for multiple analyte detection and technological advancements to support market growth
TABLE 32 FLUOROSPOT ASSAY KITS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 33 NORTH AMERICA: FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 34 EUROPE: FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 35 ASIA PACIFIC: FLUOROSPOT ASSAY KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.2.2 ASSAY KITS MARKET, BY UTILITY
TABLE 36 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY UTILITY, 2020–2028 (USD MILLION)
6.2.2.1 Diagnostic kits
6.2.2.1.1 Need for early diagnosis of infections to drive market
TABLE 37 CANCER CASES, BY TYPE, 2020
TABLE 38 DIAGNOSTIC KITS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 39 NORTH AMERICA: DIAGNOSTIC KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 40 EUROPE: DIAGNOSTIC KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 41 ASIA PACIFIC: DIAGNOSTIC KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.2.2.2 Research kits
6.2.2.2.1 Increasing investments in vaccine research, clinical trials, and cancer research to drive market
TABLE 42 RESEARCH KITS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 43 NORTH AMERICA: RESEARCH KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 44 EUROPE: RESEARCH KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 45 ASIA PACIFIC: RESEARCH KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.2.3 ASSAY KITS MARKET, BY ANALYTE
TABLE 46 ELISPOT AND FLUOROSPOT ASSAY KITS MARKET, BY ANALYTE, 2020–2028 (USD MILLION)
6.2.3.1 T-cell-based kits
6.2.3.1.1 Low concentrations of infection-released analytes necessitate use of T-cell-based kits
TABLE 47 T-CELL-BASED KITS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 48 NORTH AMERICA: T-CELL-BASED KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 49 EUROPE: T-CELL-BASED KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 50 ASIA PACIFIC: T-CELL-BASED KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.2.3.2 B-cell-based kits
6.2.3.2.1 Detection of B-cell-based antibodies useful to study cell response post-infection/vaccination
TABLE 51 B-CELL-BASED KITS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 52 NORTH AMERICA: B-CELL-BASED KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 53 EUROPE: B-CELL-BASED KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 54 ASIA PACIFIC: B-CELL-BASED KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.2.3.3 Other analyte kits
TABLE 55 OTHER ANALYTE KITS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 56 NORTH AMERICA: OTHER ANALYTE KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 57 EUROPE: OTHER ANALYTE KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 58 ASIA PACIFIC: OTHER ANALYTE KITS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.3 ANALYZERS
6.3.1 ADOPTION OF ASSAY KITS TO DRIVE USE OF ANALYZERS
TABLE 59 ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 60 NORTH AMERICA: ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 61 EUROPE: ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 62 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ANALYZERS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
6.4 ANCILLARY PRODUCTS
6.4.1 REPEATED USAGE OF ANCILLARY PRODUCTS INTEGRAL TO RELIABILITY AND SUCCESS OF ELISPOT AND FLUOROSPOT ASSAYS
TABLE 63 ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY REGION, 2020–2028 (USD MILLION)
TABLE 64 NORTH AMERICA: ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 65 EUROPE: ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 66 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ANCILLARY PRODUCTS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
7 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION
7.1 INTRODUCTION
TABLE 67 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
7.2 DIAGNOSTIC APPLICATIONS
TABLE 68 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2020–2028 (USD MILLION)
TABLE 69 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2028 (USD MILLION)
TABLE 70 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 71 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 72 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2028 (USD MILLION)
7.2.1 INFECTIOUS DISEASES
7.2.1.1 Rising prevalence of infectious diseases to drive market
TABLE 73 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2028 (USD MILLION)
TABLE 74 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 75 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 76 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2028 (USD MILLION)
7.2.2 TRANSPLANTS
7.2.2.1 Growing incidence of infections caused during transplant procedures to drive demand
FIGURE 33 PATIENTS ON WAITING LIST FOR ORGAN TRANSPLANTS, 2023
FIGURE 34 NUMBER OF TRANSPLANTS PERFORMED IN 2023
TABLE 77 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY REGION, 2020–2028 (USD MILLION)
TABLE 78 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 79 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 80 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR TRANSPLANTS, BY COUNTRY, 2020–2028 (USD MILLION)
7.3 RESEARCH APPLICATIONS
TABLE 81 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2028 (USD MILLION)
TABLE 82 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2028 (USD MILLION)
TABLE 83 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 84 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 85 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2028 (USD MILLION)
7.3.1 VACCINE DEVELOPMENT
7.3.1.1 Largest and fastest-growing segment of market
TABLE 86 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY REGION, 2020–2028 (USD MILLION)
TABLE 87 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 88 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 89 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2020–2028 (USD MILLION)
7.3.2 CLINICAL TRIALS
7.3.2.1 Growing number of clinical trials to drive demand
FIGURE 35 NUMBER OF CLINICAL TRIALS, BY REGION, 2010–2021
FIGURE 36 NUMBER OF REGISTERED CLINICAL STUDIES, 2023
TABLE 90 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY REGION, 2020–2028 (USD MILLION)
TABLE 91 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 92 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 93 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2020–2028 (USD MILLION)
7.3.3 CANCER RESEARCH
7.3.3.1 Rising prevalence of cancer to support market growth
TABLE 94 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY REGION, 2020–2028 (USD MILLION)
TABLE 95 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 96 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 97 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR CANCER RESEARCH, BY COUNTRY, 2020–2028 (USD MILLION)
8 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER
8.1 INTRODUCTION
TABLE 98 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
8.2 HOSPITAL AND CLINICAL LABORATORIES
8.2.1 IMPROVING HEALTHCARE INFRASTRUCTURE IN DEVELOPING COUNTRIES TO DRIVE MARKET
TABLE 99 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY REGION, 2020–2028 (USD MILLION)
TABLE 100 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 101 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 102 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR HOSPITAL AND CLINICAL LABORATORIES, BY COUNTRY, 2020–2028 (USD MILLION)
8.3 RESEARCH INSTITUTES
8.3.1 FASTEST-GROWING END USER OF ELISPOT AND FLUOROSPOT ASSAYS
TABLE 103 GRANTS, BY CANCER TYPE, 2023
TABLE 104 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2020–2028 (USD MILLION)
TABLE 105 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 106 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 107 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020–2028 (USD MILLION)
8.4 BIOPHARMACEUTICAL COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS
8.4.1 GROWTH IN BIOTECHNOLOGY INDUSTRY TO PROPEL GROWTH
TABLE 108 ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY REGION, 2020–2028 (USD MILLION)
TABLE 109 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 110 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 111 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET FOR BIOPHARMACEUTICAL COMPANIES AND CROS, BY COUNTRY, 2020–2028 (USD MILLION)
9 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION
9.1 INTRODUCTION
TABLE 112 ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY REGION, 2020–2028 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 37 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET SNAPSHOT
TABLE 113 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 114 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 115 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 116 NORTH AMERICA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.2.1 NORTH AMERICA: RECESSION IMPACT
9.2.2 US
9.2.2.1 Rising prevalence of chronic diseases to drive market
TABLE 117 US: KEY MACROINDICATORS
TABLE 118 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 119 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 120 US: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.2.3 CANADA
9.2.3.1 Rising healthcare expenditure to drive adoption of ELISpot and FluoroSpot assays
TABLE 121 CANADA: KEY MACROINDICATORS
TABLE 122 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 123 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 124 CANADA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.3 EUROPE
TABLE 125 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY
9.3.1 EUROPE: RECESSION IMPACT
TABLE 126 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 127 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 128 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 129 EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.3.2 GERMANY
9.3.2.1 Fastest-growing country in European ELISpot and FluoroSpot assays market
TABLE 130 GERMANY: KEY MACROINDICATORS
TABLE 131 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 132 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 133 GERMANY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.3.3 UK
9.3.3.1 Rising prevalence of NCDs to drive market
TABLE 134 UK: KEY MACROINDICATORS
TABLE 135 UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 136 UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 137 UK: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.3.4 FRANCE
9.3.4.1 Need for early disease diagnosis to support market growth
TABLE 138 FRANCE: KEY MACROINDICATORS
TABLE 139 FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 140 FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 141 FRANCE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.3.5 ITALY
9.3.5.1 Increasing incidence of cancer to propel market
TABLE 142 ITALY: KEY MACROINDICATORS
TABLE 143 ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 144 ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 145 ITALY: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.3.6 SPAIN
9.3.6.1 High incidence of chronic diseases to drive market
TABLE 146 SPAIN: KEY MACROINDICATORS
TABLE 147 SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 148 SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 149 SPAIN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.3.7 REST OF EUROPE
TABLE 150 REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 151 REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 152 REST OF EUROPE: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 38 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET SNAPSHOT
TABLE 153 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY COUNTRY, 2020–2028 (USD MILLION)
TABLE 154 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 155 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 156 ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.4.2 CHINA
9.4.2.1 Rising focus on vaccine development and cancer research to drive market
TABLE 157 CHINA: KEY MACROINDICATORS
TABLE 158 CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 159 CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 160 CHINA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.4.3 JAPAN
9.4.3.1 Increased focus on vaccine research to support market growth
TABLE 161 JAPAN: KEY MACROINDICATORS
TABLE 162 JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 163 JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 164 JAPAN: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.4.4 INDIA
9.4.4.1 Increasing focus on cancer research and therapy to drive market
TABLE 165 INDIA: KEY MACROINDICATORS
TABLE 166 INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 167 INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 168 INDIA: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.4.5 REST OF ASIA PACIFIC
TABLE 169 REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 170 REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 171 REST OF ASIA PACIFIC: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
9.5 REST OF THE WORLD
TABLE 172 REST OF THE WORLD: POPULATION AGED 65 AND ABOVE, 2022
9.5.1 REST OF THE WORLD: RECESSION IMPACT
TABLE 173 REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY PRODUCT, 2020–2028 (USD MILLION)
TABLE 174 REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY APPLICATION, 2020–2028 (USD MILLION)
TABLE 175 REST OF THE WORLD: ELISPOT AND FLUOROSPOT ASSAYS MARKET, BY END USER, 2020–2028 (USD MILLION)
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 STRATEGIES ADOPTED BY KEY PLAYERS
TABLE 176 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ELISPOT AND FLUOROSPOT ASSAYS MARKET
10.3 MARKET SHARE ANALYSIS
TABLE 177 ELISPOT AND FLUOROSPOT ASSAYS MARKET: DEGREE OF COMPETITION
10.4 REVENUE SHARE ANALYSIS
FIGURE 39 REVENUE ANALYSIS OF KEY PUBLIC PLAYERS IN ELISPOT AND FLUOROSPOT ASSAYS MARKET
FIGURE 40 ELISPOT AND FLUOROSPOT ASSAYS: MARKET RANKING ANALYSIS, 2022
10.5 COMPANY EVALUATION MATRIX
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
FIGURE 41 ELISPOT AND FLUOROSPOT ASSAYS MARKET: COMPANY EVALUATION MATRIX, 2022
10.6 SME/STARTUP EVALUATION MATRIX
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
FIGURE 42 ELISPOT AND FLUOROSPOT ASSAYS MARKET: SME/STARTUP EVALUATION MATRIX, 2022
10.7 COMPETITIVE BENCHMARKING
TABLE 178 ELISPOT AND FLUOROSPOT ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
10.8 COMPANY FOOTPRINT
TABLE 179 COMPANY FOOTPRINT
TABLE 180 PRODUCT FOOTPRINT
TABLE 181 REGIONAL FOOTPRINT
10.9 COMPETITIVE SCENARIO
10.9.1 PRODUCT LAUNCHES
TABLE 182 KEY PRODUCT LAUNCHES, JANUARY 2020–OCTOBER 2023
10.9.2 DEALS
TABLE 183 KEY DEALS, JANUARY 2020–OCTOBER 2023
10.9.3 OTHER DEVELOPMENTS
TABLE 184 OTHER KEY DEVELOPMENTS, JANUARY 2020–OCTOBER 2023
11 COMPANY PROFILES
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
11.1 KEY PLAYERS
11.1.1 OXFORD IMMUNOTEC USA, INC. (SUBSIDIARY OF REVVITY, INC.)
TABLE 185 OXFORD IMMUNOTEC USA, INC. (SUBSIDIARY OF REVVITY, INC.): BUSINESS OVERVIEW
FIGURE 43 REVVITY, INC.: COMPANY SNAPSHOT (2023)
11.1.2 BECTON, DICKINSON AND COMPANY
TABLE 186 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 44 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
11.1.3 BIO-TECHNE
TABLE 187 BIO-TECHNE: BUSINESS OVERVIEW
FIGURE 45 BIO-TECHNE: COMPANY SNAPSHOT (2023)
11.1.4 CELLULAR TECHNOLOGY LIMITED
TABLE 188 CELLULAR TECHNOLOGY LIMITED: BUSINESS OVERVIEW
11.1.5 MABTECH
TABLE 189 MABTECH: BUSINESS OVERVIEW
11.1.6 ABCAM PLC
TABLE 190 ABCAM PLC: BUSINESS OVERVIEW
FIGURE 46 ABCAM PLC: COMPANY SNAPSHOT (2022)
11.1.7 MERCK KGAA
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 47 MERCK KGAA: COMPANY SNAPSHOT (2022)
11.1.8 AUTOIMMUN DIAGNOSTIKA GMBH
TABLE 192 AUTOIMMUN DIAGNOSTIKA GMBH: BUSINESS OVERVIEW
11.1.9 U-CYTECH
TABLE 193 U-CYTECH: BUSINESS OVERVIEW
11.1.10 MIKROGEN DIAGNOSTIK
TABLE 194 MIKROGEN DIAGNOSTIK: BUSINESS OVERVIEW
11.1.11 MEDIX BIOCHEMICA
TABLE 195 MEDIX BIOCHEMICA: BUSINESS OVERVIEW
11.1.12 ABNOVA CORPORATION
TABLE 196 ABNOVA CORPORATION: BUSINESS OVERVIEW
11.1.13 ANOGEN-YES BIOTECH LABORATORIES LTD.
TABLE 197 ANOGEN-YES BIOTECH LABORATORIES LTD.: BUSINESS OVERVIEW
11.1.14 BIORBYT LTD.
TABLE 198 BIORBYT LTD.: BUSINESS OVERVIEW
11.1.15 BIOSYS SCIENTIFIC DEVICES GMBH
TABLE 199 BIOSYS SCIENTIFIC DEVICES GMBH: BUSINESS OVERVIEW
11.2 OTHER PLAYERS
11.2.1 JACKSON IMMUNORESEARCH INC.
TABLE 200 JACKSON IMMUNORESEARCH INC.: BUSINESS OVERVIEW
11.2.2 IST SCIENTIFIC
TABLE 201 IST SCIENTIFIC: BUSINESS OVERVIEW
11.2.3 SERVA ELECTROPHORESIS GMBH
TABLE 202 SERVA ELECTROPHORESIS GMBH: BUSINESS OVERVIEW
11.2.4 ACROBIOSYSTEMS
TABLE 203 ACROBIOSYSTEMS: BUSINESS OVERVIEW
11.2.5 NATIONAL ANALYTICAL CORPORATION
TABLE 204 NATIONAL ANALYTICAL CORPORATION: BUSINESS OVERVIEW
11.2.6 STEMCELL TECHNOLOGIES
TABLE 205 STEMCELL TECHNOLOGIES: BUSINESS OVERVIEW
11.2.7 ZENBIO, INC.
TABLE 206 ZENBIO, INC.: BUSINESS OVERVIEW
11.2.8 BOC SCIENCES
TABLE 207 BOC SCIENCES: BUSINESS OVERVIEW
11.2.9 TOKYO CHEMICAL INDUSTRY CO., LTD.
TABLE 208 TOKYO CHEMICAL INDUSTRY CO., LTD.: BUSINESS OVERVIEW
11.2.10 MP BIOMEDICALS
TABLE 209 MP BIOMEDICALS: BUSINESS OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
12 APPENDIX
12.1 INSIGHTS FROM INDUSTRY EXPERTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 CUSTOMIZATION OPTIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS
